<DOC>
	<DOCNO>NCT00813826</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety SLC022 treat pain associate post-herpetic neuralgia ( PHN ) recently diagnose patient .</brief_summary>
	<brief_title>Efficacy Safety Study SLC022 Treating Pain Associated With Post Herpetic Neuralgia</brief_title>
	<detailed_description>This study enroll subject establish PHN , stable pain intensity meet eligibility criterion .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<criteria>1 . Male female age 18 year old . 2 . A history cutaneous herpes zoster infection sustain pain associate site herpes zoster skin rash &gt; 6 month , onset herpes zoster skin rash . 3 . Well establish consistent pain baseline phase . 4 . Completed washout period 7 day exist pain medication . 5 . Evidence personally sign date informed consent document indicate subject inform pertinent aspect study . 6 . A willingness ability comply schedule visit , treatment plan , laboratory test , study procedure . 1 . Pregnant breast feeding . 2 . Female subject surgically sterile ( hysterectomy bilateral tubal ligation ) , postmenopausal least one year , willing practice adequate method contraception childbearing potential . 3 . Previous neurolytic neurosurgical therapy PHN . 4 . Treatment local anesthetic nerve block within last 30 day . 5 . Failure adequate dose 3 first line drug treatment PHNrelated pain due efficacy . 6 . Any type pain may impair self assessment pain due PHN . 7 . Skin condition affect dermatome could alter sensation . 8 . Participation study within 30 day current study begin and/or study participation . 9 . Taking CYP1A2 inhibitor fluvoxamine , certain fluoroquinolones ( e.g. , ciprofloxacin , enoxacin , pefloxacin , etc ) , mexiletine , zileuton . 10 . History drug alcohol abuse last 5 year . 11 . Creatinine clearance &lt; 50 mL/min . 12 . History malignancy basal cell carcinoma carcinoma situ . 13 . History chronic hepatitis B C , human immunodeficiency virus ( HIV ) infection . 14 . Clinically significant hepatic , respiratory , hematological , cardiovascular neurological disease . 15 . Immunocompromised state . 16 . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>PHN</keyword>
	<keyword>Pain Shingles</keyword>
</DOC>